Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

GenVec begins phase I clinical trial with TNFerade

Feb. 16, 2001

Merck's new oligopeptide-cytotoxic agent conjugates useful for Rx of cancer, BPH

Feb. 16, 2001

Maxim receives SBIR grants for evaluation of anticancer agents

Feb. 16, 2001

SuperGen obtains certain rights to VTA technology

Feb. 16, 2001

Onconase receives orphan medicinal product designation in Europe

Feb. 15, 2001

Antitumor agents derived from UCF-116 result from Kyowa Hakko-Lilly collaboration

Feb. 15, 2001

Two of British Biotech's MMPIs show no advantage over placebo

Feb. 15, 2001

Licensing opportunity from NIH: NSAID-related gene with antitumorigenic properties

Feb. 15, 2001

Ilex Oncology acquires Symphar; Symphar becomes Ilex Research-Europe

Feb. 14, 2001

Genta's Genasense enters phase III evaluation for multiple myeloma

Feb. 14, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...